These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 24944070)

  • 1. A chart review based comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment center.
    Balhara YP
    J Opioid Manag; 2014; 10(3):200-6. PubMed ID: 24944070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings.
    Murphy SM; Dweik D; McPherson S; Roll JM
    Am J Drug Alcohol Abuse; 2015 Jan; 41(1):88-92. PubMed ID: 25490610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
    Winstock AR; Lea T; Ritter A
    Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.
    Pérez de los Cobos J; Martin S; Etcheberrigaray A; Trujols J; Batlle F; Tejero A; Queraltó JM; Casas M
    Drug Alcohol Depend; 2000 Jun; 59(3):223-33. PubMed ID: 10812283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2000 Feb; 58(1-2):143-52. PubMed ID: 10669065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
    Marsch LA; Bickel WK; Badger GJ; Jacobs EA
    Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial.
    Assadi SM; Hafezi M; Mokri A; Razzaghi EM; Ghaeli P
    J Subst Abuse Treat; 2004 Jul; 27(1):75-82. PubMed ID: 15223097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling.
    Kornør H; Waal H; Ali RL
    Drug Alcohol Rev; 2006 Mar; 25(2):123-30. PubMed ID: 16627301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
    Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine prescribing practices and exposures reported to a poison center--Utah, 2002-2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(49):997-1001. PubMed ID: 23235296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.